GemcitabineRecent, repeatedEvidence- NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · background · “Gemcitabine” · registered Jul 2026
- NCT07398339 · Shanghai Guangsheng Biopharmaceutical Co., Ltd · Phase 2 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Jan 2026
- NCT07229625 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Nov 2025
- NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Aug 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 912 studies | 912 studies | background 16 · comparator 3 |
CisplatinRecent, repeatedEvidence- NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · background · “Cisplatin” · registered Jul 2026
- NCT07398339 · Shanghai Guangsheng Biopharmaceutical Co., Ltd · Phase 2 · live · background · “Cisplatin for injection” · registered Jan 2026
- NCT07229625 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Cisplatin Injection” · registered Nov 2025
- NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Cisplatin for Injection” · registered Aug 2025
- NCT06591520 · Akeso · Phase 3 · live · comparator · “Durvalumab, Gemcitabine, Cisplatin” · registered Sep 2024
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 912 studies | 912 studies | background 16 · comparator 2 |
pembrolizumabRecent, repeatedEvidence- NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · comparator · “Pembrolizumab” · registered Jul 2026
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT06978114 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered May 2025
- NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Pembrolizumab” · registered Feb 2024
- NCT05429697 · SMT bio Co., Ltd. · Phase 3 · live · background · “Pembrolizumab” · registered Jun 2022
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 55 studies | 55 studies | background 5 · comparator 1 |
durvalumabRecent, repeatedEvidence- NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · comparator · “Durvalumab” · registered Jul 2026
- NCT07229625 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Durvalumab Injection” · registered Nov 2025
- NCT06591520 · Akeso · Phase 3 · live · comparator · “Durvalumab, Gemcitabine, Cisplatin” · registered Sep 2024
- NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Durvalumab” · registered Feb 2024
- NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Durvalumab” · registered Feb 2023
| AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018) | 55 studies | 55 studies | background 2 · comparator 3 |
CapecitabineRecent, repeatedEvidence- NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Capecitabine Tablets” · registered May 2026
- NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Capecitabine” · registered May 2026
- NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Capecitabine Tablets” · registered Aug 2025
- NCT06622057 · InnoPharmax Inc. · Phase 3 · live · background · “Capecitabine” · registered Sep 2024
- NCT06109779 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Oct 2023
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 46 studies | 46 studies | background 5 · comparator 3 |
BevacizumabRecent, repeatedEvidence- NCT06465563 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab Injection” · registered Jun 2024
- NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Feb 2023
- NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
- NCT03929666 · Jazz Pharmaceuticals · Phase 2 · background · “Bevacizumab” · registered Feb 2019
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 44 studies | 44 studies | background 5 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT05771480 · AstraZeneca · Phase 3 · live · background · “Gemcitabine + cisplatin + albumin-bound paclitaxel” · registered Mar 2023
- NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Abraxane” · registered Jul 2022
- NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Nab-Paclitaxel” · registered Jan 2022
- NCT04683939 · BioNTech SE · Phase 2 · background · “Nab-paclitaxel” · registered Dec 2020
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 44 studies | 33 studies | background 5 |
FluorouracilRecent, repeatedEvidence- NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Fluorouracil” · registered May 2026
- NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Fluorouracil” · registered May 2026
- NCT06428409 · Merck & Co., Inc · Phase 2 · live · background · “Fluorouracil (5-FU)” · registered May 2024
- NCT06219941 · AstraZeneca · Phase 2 · live · background · “5-Fluorouracil” · registered Nov 2023
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “5-Fluorouracil” · registered Jul 2022
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 35 studies | 35 studies | background 5 · comparator 3 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Oxaliplatin” · registered May 2026
- NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Oxaliplatin” · registered May 2026
- NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Oxaliplatin Injection” · registered Aug 2025
- NCT05771480 · AstraZeneca · Phase 3 · live · background · “Gemcitabine + oxaliplatin” · registered Mar 2023
- NCT03929666 · Jazz Pharmaceuticals · Phase 2 · background · “Oxaliplatin” · registered Feb 2019
| Sanofi35% of its industry studies | 34 studies | 34 studies | background 4 · comparator 3 |
IrinotecanRecent, repeatedEvidence- NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan Hydrochloride” · registered May 2026
- NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan Hydrochloride” · registered May 2026
- NCT06219941 · AstraZeneca · Phase 2 · live · background · “Irinotecan” · registered Nov 2023
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 34 studies | 34 studies | background 2 · comparator 2 |
PaclitaxelRecent, repeatedEvidence- NCT05506943 · Compass Therapeutics · Phase 3 · live · background · “Paclitaxel” · registered Aug 2022
- NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Paclitaxel” · registered Jul 2022
- NCT04644068 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Oct 2020
- NCT03314935 · Incyte Corporation · Phase 2 · background · “Paclitaxel” · registered Oct 2017
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 22 studies | 33 studies | background 4 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT05771480 · AstraZeneca · Phase 3 · live · background · “Gemcitabine + carboplatin” · registered Mar 2023
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2022
- NCT04956640 · Eli Lilly and Company · Phase 2 · live · background · “Carboplatin” · registered Jul 2021
- NCT04644068 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Oct 2020
| Eli Lilly and Company16% of its industry studies | 23 studies | 35 studies | background 5 |
CetuximabRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
- NCT06024174 · Bristol-Myers Squibb · Phase 2 · background · “Cetuximab” · registered Aug 2023
| Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004) | 22 studies | 11 study | background 2 |
atezolizumabRecent, repeatedEvidence- NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Feb 2023
- NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Atezolizumab” · registered Jan 2022
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 22 studies | 11 study | background 2 |